Skip to main content

Advertisement

Table 3 Biologics/tofacitinib index prescriptions, filling/administration status, and discrepancies between index prescription and first filling/administration post index

From: Factors associated with physicians’ prescriptions for rheumatoid arthritis drugs not filled by patients

Index prescription drug Total number of patients (a + b) Number of patients with no B/T filled/administered within 3 months, n (%) (a) Number of patients with ≥1 B/T filled/administered within 3 months, n (%) (b) First B/T filled/administered after index that was different from the index prescription (among b)
Anti-TNF biologics
 Adalimumab (SC) 118 56 (47.5) 62 (52.5) 10 etanercept
 Certolizumab (SC) 11 6 (54.5) 5 (45.5) 1 certolizumab IV
 Etanercept (SC) 202 65 (32.2) 137 (67.8) 1 adalimumab
 Golimumab (SC) 17 8 (47.1) 9 (52.9) None
 Golimumab (IV) 1   1 (100.0) None
 Infliximab (IV) 28 14 (50.0) 14 (50.0) None
Non-anti-TNF biologics
 Abatacept (IV) 23 8 (34.8) 15 (65.2) 5 abatacept SC
 Abatacept (SC) 9 5 (55.6) 4 (44.4) None
 Anakinra (SC) 1   1 (100.0) None
 Rituximab (IV) 7 4 (57.1) 3 (42.9) 1 abatacept SC
 Tocilizumab (IV) 2 1 (50.0) 1 (50.0) None
 Tocilizumab (SC) 1 1 (100.0)  
New synthetic DMARD
 Tofacitinib (oral) 14 8 (57.1) 6 (42.9) None
Total 434 176 (40.6) 258 (59.4) 18 discrepancies
  1. B/T biologics/tofacitinib, TNF tumor necrosis factor, SC subcutaneous, IV intravenous infusion, DMARD disease-modifying anti-rheumatic drug